首页> 外文期刊>Retina >Intravitreal bevacizumab in vascular pigment epithelium detachment as a result of subfoveal occult choroidal neovascularization in age-related macular degeneration.
【24h】

Intravitreal bevacizumab in vascular pigment epithelium detachment as a result of subfoveal occult choroidal neovascularization in age-related macular degeneration.

机译:玻璃体腔内贝伐单抗在年龄相关性黄斑变性中由于中央凹下隐性脉络膜新血管形成而引起的血管色素上皮脱离。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: The purpose of this study was to evaluate the effect of intravitreally administered bevacizumab on untreated vascularized pigment epithelium detachment (PED) in sub- or juxtafoveal occult choroidal neovascularization as a result of age-related macular degeneration. METHODS: In this retrospective study, 28 untreated eyes of 26 patients (4 men, 22 women; mean age, 74.6 +/- 7.2 years) with PED and sub- or juxtafoveal occult choroidal neovascularization as a result of age-related macular degeneration and additional intra- and/or subretinal fluid were treated with intravitreal injections of 1.25 mg bevacizumab. Baseline and follow-up visits included best-corrected visual acuity, complete ophthalmic examination, and Stratus optical coherence tomography. Fluorescein angiography was performed at baseline. Reinjections were performed if intra- and/or subretinal fluid persisted or recurred or PED increased. RESULTS: Patients received 3.2 +/- 1.8 injections (follow-up 37.9 +/- 18.3 weeks). Mean maximum PED height showed a tendency to decrease (372 +/- 150.5 mum to 290.3 +/- 189 mum; P = 0.094). In 14 eyes (53.8%), PED height was reduced at last visit, including complete flattening in 1 eye. Mean visual acuity remained stable (0.58 +/- 0.30 logarithm of the minimum angle of resolution to 0.58 +/- 0.37 logarithm of the minimum angle of resolution; P = 0.905). Pigment epithelium detachment response to treatment did not correlate with baseline PED height or visual acuity at baseline or at the last visit. One patient sustained a retinal pigment epithelium rip, and another patient sustained an extensive subretinal hemorrhage. CONCLUSION: During bevacizumab therapy, mean PED height decreases in 50% of patients. No predictive factors for the response of PED to bevacizumab treatment could be identified. Treatment of PED with bevacizumab might result in a long-term functional benefit compared with the natural course.
机译:目的:本研究的目的是评估玻璃体内注射贝伐单抗对年龄相关性黄斑变性导致的亚凹或近睑凹隐性脉络膜新血管形成中未治疗的血管化色素上皮脱离(PED)的影响。方法:在这项回顾性研究中,由于年龄相关的黄斑变性和黄斑变性,导致26例PED并伴有近凹或近中凹隐性脉络膜新生血管的28例未经治疗的眼睛(4例男性,22例女性;平均年龄74.6 +/- 7.2岁)。再用1.25 mg贝伐单抗玻璃体内注射来治疗另外的视网膜内和/或视网膜下液。基线和随访包括最佳矫正视力,完整的眼科检查和Stratus光学相干断层扫描。基线进行荧光素血管造影。如果视网膜内和/或视网膜下液持续存在或复发或PED增加,则进行再次注射。结果:患者接受了3.2 +/- 1.8针注射(随访37.9 +/- 18.3周)。平均最大PED高度呈下降趋势(372 +/- 150.5微米至290.3 +/- 189微米; P = 0.094)。在14眼(53.8%)中,PED高度在上次访视时降低了,包括1眼完全变平。平均视力保持稳定(最小分辨角的0.58 +/- 0.30对数至最小分辨角的0.58 +/- 0.37对数; P = 0.905)。对治疗的色素上皮脱离反应与基线或最后一次访视时的基线PED高度或视敏度不相关。一名患者视网膜色素上皮撕裂,另一名患者视网膜下广泛出血。结论:贝伐单抗治疗期间,平均PED高度降低了50%的患者。无法确定PED对贝伐单抗治疗反应的预测因素。与自然疗程相比,用贝伐单抗治疗PED可能会产生长期的功能益处。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号